Prescient Therapeutics Ltd has released a press release.
June 2025 Quarterly Update and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- Prescient announces results of SPP & Launches Placement
- Trading Halt
- Prescient Therapeutics - Extension of Share Purchase Plan
- PTX Opens First U.S. Site for PTX-100 Phase 2a Trial
- Prescient Therapeutics Extends Share Purchase Plan
Later from Prescient Therapeutics
- Prescient successfully completes $3 million Placement
- Appendix 4E and 2025 Annual Report
- September Quarterly Updated and Appendix 4C
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- PTX secures EU Authorisation to commence PTX-100 Trial
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics